Phathom Pharmaceuticals (PHAT) will release its next earnings report on Nov 5, In the last quarter Phathom Pharmaceuticals reported -$ EPS in. Phathom Pharmaceuticals, Inc. (NasdaqGS:PHAT) institutional ownership structure shows current positions in the company by institutions and funds, as well as. As of Sep the stock price of Phathom Pharmaceuticals is $ What is the current market cap of Phathom Pharmaceuticals? The current market. Phathom Pharmaceuticals NasdaqGS:PHAT Stock Report ; Last Price. US$ ; Market Cap. US$b ; 7D. % ; 1Y. % ; Updated. 05 Sep, Track Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote, latest community messages, chart, news and other stock related information.
Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported earnings for the second quarter with a net loss of $ per share, versus the expected loss of $ PHAT vs Biotech Stocks ; $, $, +%, Buy ; $, $, +%, Strong Buy. Phathom Pharmaceuticals Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - share of Common Stock during the period from the grant date of the share of Phantom Stock to the date on which the share vests. Stock Bonus awards are. Phathom Pharmaceuticals Number of Employees | PHAT ; Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on. View live Phathom Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, PHAT financials and market news PHAT Phantom Pharma. The average price target for Phathom Pharmaceuticals is $ This is based on 4 Wall Streets Analysts month price targets, issued in the past 3 months. The average additional pay is $72K per year, which could include cash bonus, stock, commission, profit sharing or tips. PHARMACEUTICALS, INC. (the “Company”) common stock (the “Target PSU Phantom Stock”) (each such unit, a “Performance Restricted Stock Unit”) with. Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for. This is an initial public offering of shares of common stock of Phathom Pharmaceuticals, Inc. We are offering shares of our common stock.
Phathom Pharmaceuticals' stock was trading at $ at the beginning of the year. Since then, PHAT stock has increased by % and is now trading at $ Phathom Pharmaceuticals Announces Pricing of $ Million Offering of Common Stock and Pre-Funded Warrants. GlobeNewswire • 22 days ago. The Phathom Pharmaceuticals, Inc. stock price fell by % on the last day (Friday, 6th Sep ) from $ to $ During the last trading day the stock. View Phathom Pharmaceuticals, Inc PHAT investment & stock information. Get the latest Phathom Pharmaceuticals, Inc PHAT detailed stock quotes, stock data. Discover real-time Phathom Pharmaceuticals, Inc. Common Stock (PHAT) stock prices, quotes, historical data, news, and Insights for informed trading and. As of Sep the stock price of Phathom Pharmaceuticals is $ What is the current market cap of Phathom Pharmaceuticals? The current market. Stock Quote ; Change; (%) ; Volume; 1,, ; Today's Open; $ ; Previous Close; $ Phathom Pharmaceuticals, Inc.'s stock symbol is PHAT and currently trades under NASDAQ. It's current price per share is approximately $ What are your. Find annual and quearterly earnings data for Phathom Pharmaceuticals, Inc. Common Stock (PHAT) including earnings per share, earnings forecasts at.
phantom stock account in a lump sum or in installments over time) a distribution from his phantom stock account in our ordinary shares. The Directors. Phathom Pharmaceuticals Inc PHAT:NASDAQ ; Close. quote price arrow down (%) ; Volume. , ; 52 week range. - Phathom Pharmaceuticals stock price forecast: $24; Market Cap: M, Enterprise value: M, P/E: , PEG ratio: , EPS: , Revenue: N/A. Phathom Pharmaceuticals is a small cap company so has lots of potential for movement. May be worth looking into for a short term trade. Organization · Phathom Pharmaceuticals Announces Pricing of $ Million Offering of Common Stock and Pre-Funded Warrants · Phathom Pharmaceuticals Reports Second.
Phantom Pharmaceuticals gets FDA approval for Erosive GERD drug, Seeking Alpha. , 12 Health Care Stocks Moving In Wednesday's After-Market Session.